Monitor the ASCO presentation on June 1 for initial clinical activity and safety signals in the azenosertib-paclitaxel arm. While this is not a pivotal readout, positive data could expand azenosertib’s franchise potential beyond monotherapy and support future combination strategies.
ZNTL drugs
ZNTL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 21 $3.99entry
- T+1 · 7mo ago −3.76%α −4.78% · $3.84
- T+5 · 7mo ago +1.50%α +0.42% · $4.05
- T+20 · 6mo ago −9.02%α −13.94% · $3.63
- T+60 · 4mo ago +14.54%α +7.64% · $4.57
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zentalis Pharmaceuticals announced that data from Part 1 of its MUIR trial, evaluating azenosertib in combination with paclitaxel for platinum-resistant ovarian cancer, will be presented at the 2026 ASCO Annual Meeting. While the abstract acceptance signals growing clinical interest, no efficacy or safety data are being released yet, and the event is informational rather than data-driven.
Key Facts
- Abstract on azenosertib + paclitaxel in platinum-resistant ovarian cancer accepted for poster presentation at ASCO 2026.
- Presentation scheduled for June 1, 2026, during the Gynecologic Cancer poster session.
- Data to be presented are from Part 1 of the Phase 1b MUIR trial, focusing on safety and preliminary activity.
- Azenosertib remains in late-stage development as monotherapy for Cyclin E1-positive PROC, with pivotal DENALI and ASPENOVA trials ongoing.
- Azenosertib has Fast Track Designation from the FDA for Cyclin E1-positive platinum-resistant ovarian cancer.
Financial Impact
No immediate financial impact; potential future upside if data support registrational path for combination use.
Risk Factors
- Interim or preliminary data may not translate into meaningful clinical benefit.
- Combination regimens may face higher safety hurdles or limited differentiation from existing therapies.
- Zentalis remains dependent on a single asset (azenosertib) with no approved products.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278159 |
Track record
18 reports on ZNTL
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 6 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
- Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
- Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
- Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
- Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
- May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers